Announced Sat, 7 Feb · 15:08 IST

Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve Un-audited ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Welcure Drugs & Pharmaceuticals has informed BSE that its Board of Directors will meet on Thursday, February 12, 2026, at its registered office in Laxmi Nagar, New Delhi. The main agenda is to consider and approve the Un-audited Financial Results for the quarter and nine months ended December 31, 2025, along with the Limited Review Report. Any other incidental and ancillary business matters may also be taken up. The trading window for designated persons and their immediate relatives remains closed from January 1, 2026 until 48 hours after the results are formally declared.

Likely market impact

This is a routine regulatory intimation and does not disclose any financial figures itself. Investors should watch for the actual Q3 FY26 results on or after February 12, 2026, which will give the first real read on the company's performance for the October-December 2025 quarter.